08 July 2021
The European Parliament has voted to give greater powers to the European Medicines Agency (EMA) to help it better manage public health crises and improve access to critical medicines and medical devices for consumers.
22 June 2021
The EU institutions have struck a long overdue deal that will require Member States to carry out joint assessments of medicines and other health technologies for the EU market.
10 February 2021
BEUC welcomes today’s European Commission decision that renders legally binding commitments by pharma company Aspen to reduce significantly the prices of certain anti-cancer drugs (by on average 73% in Europe for the next 10 years). The decision follows a Commission antitrust investigation opened in May 2017 into whether Aspen breached EU antitrust rules’ ban on dominant companies imposing unfair prices.
Our work areas
As consumers are faced with a growing amount of information from different sources, we advocate for high quality and non-promotional information about health products.
The ageing of the population, rising healthcare costs and the economic crisis are challenging the sustainability of healthcare systems and consumers’ access to treatments.
Health scandals such as the weight-loss drug Mediator and the faulty PIP breast implants keep undermining consumers’ confidence in the safety of available health products and their oversight by the competent authorities.
- Ensure consumers have access to high quality healthcare in all EU Member States
- Guarantee consumers benefit from safe and innovative treatments
- Allow consumers to make informed choices regarding their health